[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Universitari de Bellvitge\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":683},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,45,80,108,139,189,216,246,286,312,334,354,383,410,435,459,480,505,532,558,584,606,635,661],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100589500","effect-of-alcohol-sclerotherapy-on-pelvic-pain-and-quality-of-life-in-women-with-ovarian-endometriosis-100589500",false,"NCT06955221","Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis","Effect of US-guided Alcohol Sclerotherapy for Endometriomas on Pelvic Pain and Quality of Life","ESCOMA","Inclusion Criteria:\n\n* Female sex\n* Age ≥18 and ≤45 years\n* Ultrasound suspicion of unilocular endometrioma or with a thin septum less than 3 mm\n* Size between 30-100 mm, persistent for at least 3-6 months since diagnosis\n* Ca125 marker \\\u003C300 UI\u002FmL and HE4 \\\u003C 70 pM\n* Signed informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>45 years\n* History of ovarian or uterine cancer\n* Endometrioma size \\\u003C30 mm or \\>100 mm\n* Indication for surgical treatment of the endometrioma due to suspected severe extra-ovarian endometriosis or any other cause\n* Ultrasound suspicion of dermoid cysts, anechoic cysts, or cysts with high risk of malignancy\n* Ca125 \\>300 UI\u002FmL\n* HE4 \\>70 pM\n* Pregnant women\n* Patients who do not wish to participate in the study or who are mentally incapacitated","FEMALE","18 Years","45 Years",{"count":21,"type":22},288,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to evaluate whether ultrasound-guided alcohol sclerotherapy can improve pelvic pain and quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas, compared to expectant management.\n\nThe main questions it aims to answer are:\n\n1. \\- Does sclerotherapy significantly reduce pelvic pain compared to expectant management?\n2. \\- Does sclerotherapy improve quality of life as measured by the EHP-5 score?\n\nResearchers will compare the sclerotherapy group to the expectant management group to determine whether the intervention leads to greater improvement in pain and quality of life.\n\nParticipants will:\n\n* Be randomly assigned to one of two groups: (1) Sclerotherapy group: undergo ultrasound-guided puncture and alcohol sclerotherapy; (2) Control group: expectant management\n* Complete quality of life and pain assessments at baseline and after 6 months\n* Provide blood and urine samples for biomarker analysis (e.g., cortisol, IL-6, hsCRP, catecholamines)\n* Undergo ovarian reserve assessments (AMH, antral follicle count)\n* Be followed for adverse events, recurrence, fertility outcomes, and treatment-related costs\n\nThe study will follow an intention-to-treat and per-protocol analysis approach.",[28,29,30,31],"Endometrioma","Ultrasound Therapy; Complications","Quality of Life","Pelvic Pain","RECRUITING","2026-06-27",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2025-01-01",{"date":40,"type":22},"2027-12-31",{"name":42,"class":43},"Hospital Universitari de Bellvitge","OTHER",28,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100644394","the-shape-project-hospital-system-for-physical-activity-and-active-participation-after-hospitalized-decompensation-of-respiratory-chronic-diseases-100644394","NCT07663955","The SHAPE Project (Hospital System for Physical Activity and Active Participation) After Hospitalized Decompensation of Respiratory Chronic Diseases","The SHAPE Project (Hospital System for Physical Activity and Active Participation) After Hospitalized Decompensation of Respiratory Chronic Disease in Respiratory Patients","SHAPE","Inclusion Criteria:\n\n* Age 65 years or older\n* Admission at risk of functional decline (hospital admission lasting \\> 5 days) Discharge destination: Home or residence where the patient lived prior to admission\n* Favorable multidisciplinary assessment by the healthcare team responsible for the patient during admission regarding the patient's physical fitness to perform the SHAPE program\n\nExclusion Criteria:\n\n* Explicit decision by the patient not to participate\n* Musculoskeletal problem that limits mobility\n* Limiting sociopathy (socio-family environment not optimal to guarantee program adherence)\n* Drug dependence (condition at discharge not optimal to guarantee program adherence)\n* Insufficient digital literacy and\u002For lack of online resources that do not guarantee participation in telematic sessions\n* Discharge destination: Long-term convalescent care center\n* Advanced and\u002For terminal stage of lung disease (patients with the following resources activated: Home Care and Support Teams Program for advanced disease (PADES), intensive home care at discharge due to extreme frailty (AT-DOM), advanced chronic disease requiring palliative care and a life expectancy of 12 months or less (MACA))Unstable underlying non-pulmonary disease (whether medical or mental, for example: acute myocardial infarction) Recent myocardial infarction (MI), recent stroke, recent hospitalization for psychiatric decompensation\\*) \\*Recent = within the last 3 months\n* Unstable underlying pulmonary disease (vital hemoptysis, new thoracic neoplasm, high-intermediate risk pulmonary thromboembolism)","ALL",{"count":55,"type":22},90,[25],"It is widely established that a lack of adapted physical activity (APA) and sedentary behaviors increase the prevalence of frailty, which exacerbates chronic diseases. Hospital stays amplify this phenomenon, leading to physical deconditioning, often irreparable, especially in older patients if it is not detected and treated promptly. To date, there is no standard of care focused on APA to address frailty acquired during hospital stays. In this context, the SHAPE project (Hospital System for Physical Activity and Active Participation) aims to prevent dependency in older adults with chronic diseases by developing an innovative patient journey based on APA. The project seeks to reduce frailty acquired during hospital stays by establishing standards for APA prescription, based on early diagnosis and intervention. SHAPE ensures equal access to care through an accessible and user-friendly web platform, designed for older users and also including those in rural areas. It fosters the resilience of healthcare systems by integrating a preventive and multidisciplinary approach into hospital treatments and optimizes resources through a tiered care model that provides progressive and personalized care.\n\nAlthough hospital stays have been shown to trigger physical deconditioning, there is no adapted physical activity program initiated by the hospital and followed at home after hospital discharge from a severe exacerbation in patients with chronic respiratory diseases. The SHAPE Project offers a highly beneficial tool for patients with acute or exacerbated chronic respiratory disease requiring hospitalization, promoting better overall recovery after discharge. Furthermore, this project will foster healthy lifestyles and promote health from a sustainability and prevention perspective. Of particular interest is the opportunity to offer a lifestyle change program (physical activity and hygiene-dietary measures) focused on respiratory patients and adapted to their specific needs. Moreover, the project is considered innovative in implementing healthy clinical practices through telemedicine. In addition, it offers post-hospital discharge services that, to date, have not been considered in a generic way for respiratory patients except in selective subgroups (post-COVID, patients included in lung transplant program, etc.).\n\nIn respiratory patients who have required high-risk admission due to decompensation, the implementation of the SHAPE program after hospital discharge as a support program that combines an adapted physical activity plan and general hygiene and dietary advice will improve the health indicators (frailty, sarcopenia, dyspnea, exercise tolerance, quality of life) of these patients.",[59,60,61,62,63],"Frailty","Sarcopenia","Hospital Discharge","Physical Activity","Acute Exacerbation Chronic Pulmonary Disease",[65,66,67,68,69],"adapted physical activity","frailty","sarcopenia","hospital discharge","acute exacerbation chronic pulmonary disease","NOT_YET_RECRUITING","2026-06-17",{"date":73,"type":36},"2026-06-23",{"date":75,"type":22},"2026-09-01",{"date":77,"type":22},"2028-03-30",{"name":42,"class":43},1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":79},"100641606","sling-vs-dynamic-shoulder-stabilizer-after-soft-tissue-shoulder-instability-surgery-slidy-100641606","NCT07644624","Sling vs. Dynamic Shoulder Stabilizer After Soft Tissue Shoulder Instability Surgery (SLIDY)","Sling vs. Dynamic Shoulder Stabilizer After Soft Tissue Shoulder Instability Surgery (\"SLIDY\"): A Pilot Randomized Controlled Trial Assessing Feasibility, Early Functional Recovery, and Structural Healing","SLIDY","Inclusion Criteria:\n\n* Adults aged ≥18 years undergoing arthroscopic soft-tissue stabilization for anterior shoulder instability (Bankart repair ± Hill-Sachs remplissage).\n* Ability and willingness to comply with the study protocol and scheduled follow-ups.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* Significant glenoid bone loss requiring bony augmentation procedures (e.g., bone block procedures, Latarjet).\n* Concomitant rotator cuff repair or fracture fixation.\n* Contraindication to MRI (e.g., pacemaker, claustrophobia, incompatible implants).\n* Cognitive impairment, language barriers, or logistical inability to attend follow-up visits.\n* Previous ipsilateral shoulder surgery.",{"count":89,"type":22},40,[25],"This randomized controlled trial seeks to address a significant clinical gap by evaluating the outcomes of two postoperative immobilization methods following arthroscopic soft tissue surgery for anterior shoulder instability: a standard static arm sling and a dynamic shoulder orthosis.",[93,94,95],"Anterior Shoulder Instability","Shoulder Instability","Shoulder Dislocation",[97,98,99,100,101],"Arthroscopic Bankart Repair","Hill-Sachs Remplissage","Dynamic Shoulder Orthosis","Postoperative Immobilization","Shoulder Rehabilitation","2026-06-15",{"date":71,"type":36},{"date":102,"type":36},{"date":106,"type":22},"2028-06-15",{"name":42,"class":43},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":118,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":127,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":79},"100642241","bellricu-project-precision-medicine-in-respiratory-intermediate-care-units-100642241","NCT07644637","BELLRICU PROJECT: Precision Medicine in Respiratory Intermediate Care Units","BELLRICU PROJECT: Precision Medicine in Respiratory Intermediate Care Units. Improvement of Risk Stratification, Mortality Prediction and clínical Decision-making (UCRI-CAT Team).","BELLRICU","Inclusion Criteria:\n\n* Acute or acute-on-chronic respiratory failure requiring non-invasive respiratory suport (NIRS) (Non-invasive ventilation or high flow nasal cannulae)\n* Neuromuscular patients requiring tracheostomy and ventilation invasive adaptation\n* Life-treating hemoptysis requiring emergent or urgent bronchial embolization (\\\u003C24 hours)\n* 4\\. Pulmonary embolism of high-intermediate risk requiring monitoring during first 24-48h of hospital admission on anticoagulation\n* Patients derived from Intensive care unit (ICU) requiring intermediate Medical step before transferred safely to conventional ward (complex respiratory weaning from invasive ventilation, high-dependency nurse cures due to limiting post-critical myopathy\n* Patients with thoracic cancer (onset or complication) of vital risk (major hemoptysis, massive pleural effusion, pericardial effusion on pre or cardiac arrest, pneumonitis related to oncological treatment with severe acute respiratory failure requiring NIRS, cava vein syndrome requiring emergent prothesis, etc...)\n* Respiratory complications after a complex interventional bronchoscopy requiring NIRS and\u002For strict monitoring: after significant bleeding, bronchial laceration, severe bronchospasm, non-controlled arrhythmia\n* Respiratory or\u002Fand cardiac intercurrent instability in a patient initially admitted to respiratory conventional ward.\n\nExclusion Criteria:\n\n* Patient's express negative to participate in the study\n* Patient already included in other simultaneous and competitive study\n* Patient cognitive deterioration that unable him to understand the study.",{"count":117,"type":22},624,"30 Days","OBSERVATIONAL","A respiratory intermediate care unit (RICU) is a monitoring and treatment area of respiratory patients who do not required admission to intensive care unit (ICU) but due to complexity, they could not be managed in conventional ward. Aim: To investigate those patients that could better benefit from RICU stay. Hypothesis: a comprehensive and integrative knowledge of all factors that intervene during the RICU admission allow determining probability of survival. Primary outcome: 1. To construct a predictive model of mortality at 30-days after RICU admission for patients admitted to the coordinator RICU based on standard biostatistics: The BELLRICU Model. Secondary outcomes: 2.1. To validate the model in another cohort of patients admitted at the same RICU. 2.2. To validate the model in an external cohort (patients admitted at the rest of Catalan active RICUs at the time of the study). 2.3. To compare the predictive capacity of the BELLRICU model with other previous validated scales but in ICU setting. 2. 4. To explore a new predictive model using artificial intelligence (AI) techniques. 2.4. To design a quick app to implement the BELLRICU model. Methodology: Longitudinal prospective study (3 years), recording variables at baseline, at RICU admission and 30-days follow-up. During the first two years, variables will be collected from the coordinator RICU to construct the BELLRICU model, being \"mortality after 30-day of RICU admission\" the dependent varialbe and using regression of cox proportional risks analysis. During the third year of the study, the BELLRICU model will be applicated to the rest of the participants RICUs in order to validate the model. Further, the predictive capacity of the BELLRICU model will be compared with the predictive capacity of previous validated scales in ICU setting and with a exploratory model using AI from BELLRICU data base.",[122,123,124,125,126],"Acute Respiratory Failure (ARF)","Intermediate Respiratory Care Unit","Respiratory Precision Medicine","Mortality Prediction","Stratification Risk",[128,129,123,130],"Acute Respiratory Failure","Non-invasive Respiratory Support","Intensive Care Unit","2026-06-12",{"date":133,"type":36},"2026-06-16",{"date":135,"type":22},"2026-06-10",{"date":137,"type":22},"2029-05-30",{"name":42,"class":43},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":151,"conditions":152,"keywords":162,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":4},"100628517","phase-4-shape-endo-pilot-randomized-trial-of-multimodal-pre-surgical-optimization-versus-standard-surgery-in-patients-with-obesity-and-early-stage-endometrial-cancer-100628517","NCT07462663","SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer","SHAPE-ENDO (Strategic Hormonal Approach & Prehabilitation in Endometrial Cancer): An Open-Label, Pilot Randomized Clinical Trial Comparing Standard Immediate Surgery Versus a Multimodal Metabolic Optimization and Prehabilitation Strategy Before Surgery in Patients With Atypical Endometrial Hyperplasia or Low-Risk Endometrioid Endometrial Cancer and BMI ≥40 kg\u002Fm²","SHAPE-ENDO","Inclusion Criteria:\n\n* Female participants ≥18 years old.\n* Histologically confirmed atypical endometrial hyperplasia\u002Fendometrial intraepithelial neoplasia (AEH\u002FEIN) or low-risk endometrioid endometrial carcinoma, grade 1 or 2.\n* Disease apparently confined to the uterine corpus, assessed by expert transvaginal ultrasound and\u002For pelvic magnetic resonance imaging.\n* Low- or intermediate-risk disease according to ESGO-ESTRO-ESP 2025 criteria, including presurgical stages IA1, IA2, or IB.\n* Negative or focal lymphovascular space invasion, if available.\n* Favorable molecular profile, if available, including POLE-mutated, p53 wild-type, MMR-deficient, or NSMP estrogen receptor-positive disease.\n* Body mass index ≥40 kg\u002Fm² at inclusion.\n* Considered a candidate for surgical treatment by the multidisciplinary tumor board.\n* Ability to understand and sign written informed consent after receiving oral and written information about the study, including acceptance of random assignment to either standard immediate surgery or the SHAPE-ENDO multimodal pre-surgical optimization strategy.\n\nExclusion Criteria:\n\n* FIGO stage IA3, IC, II, or higher disease.\n* Extensive lymphovascular space invasion, if available.\n* High-risk molecular profile, including p53-abnormal\u002Fmutated disease or NSMP estrogen receptor-negative disease.\n* Non-endometrioid histology, including serous carcinoma, clear-cell carcinoma, carcinosarcoma, mixed histology, or other high-risk histological subtypes.\n* Metastatic disease or suspicion of extrauterine disease.\n* Considered medically inoperable or \"unfit\" for surgery because of severe comorbidity, frailty, anesthetic contraindication, or any other clinical reason contraindicating surgical treatment.\n* Contraindication to GLP-1 receptor agonist therapy or progestin-based hormonal therapy, including levonorgestrel-releasing intrauterine device or oral progestins.\n* Previous pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia type 2.\n* Concurrent participation in another interventional pharmacological clinical trial.\n* Any condition that, in the investigator's judgment, may compromise participant safety, interfere with protocol compliance, or make participation inappropriate.",{"count":148,"type":22},80,[150],"PHASE4","SHAPE-ENDO is a single-center, open-label, pilot randomized clinical trial conducted at Hospital Universitari de Bellvitge in Barcelona, Spain.\n\nThe study will evaluate the feasibility, safety, and acceptability of comparing two treatment strategies in women with atypical endometrial hyperplasia\u002Fendometrial intraepithelial neoplasia or low-risk endometrioid endometrial cancer and grade III obesity, defined as BMI ≥40 kg\u002Fm².\n\nEligible participants will be randomized in a 1:1 ratio to one of two arms. The control arm will undergo standard immediate surgery according to the institutional clinical protocol. The experimental arm will receive the SHAPE-ENDO multimodal pre-surgical optimization strategy before surgery.\n\nThe SHAPE-ENDO strategy includes metabolic treatment with semaglutide\u002FWegovy®, local hormonal therapy with a levonorgestrel-releasing intrauterine device\u002FMirena® with or without oral medroxyprogesterone acetate\u002FProgevera®, a structured nutritional program, adapted physical exercise, and scheduled oncologic surveillance with clinical evaluation, imaging, and endometrial biopsy with or without hysteroscopy.\n\nThe experimental strategy will initially last 28 weeks. In participants with clinical, metabolic, or anthropometric benefit, adequate tolerance, and no evidence of tumor progression, the strategy may be extended up to 54 weeks before surgery.\n\nThe primary objective is to evaluate the feasibility, safety, and acceptability of the randomized trial design. Primary feasibility outcomes include recruitment rate, acceptance of randomization, retention, adherence to the assigned intervention, completion of the SHAPE-ENDO strategy, progression during the optimization period, and the proportion of participants in the experimental arm who reach surgery without tumor progression.\n\nSecondary outcomes include perioperative morbidity, histological response in the experimental arm, metabolic and anthropometric changes, quality of life, treatment adherence, safety and tolerability, and exploratory long-term oncologic outcomes including overall survival, recurrence-free survival, and cancer-specific survival.",[153,154,155,156,157,158,159,160,161],"Endometrial Cancer","Endometrial Cancer Stage I","Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","Atypical Endometrial Hyperplasia","Endometrial Intraepithelial Neoplasia","Obesity & Overweight","BMI>40","Obesity","Obesity Grade III",[163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181],"Semaglutide","GLP-1 receptor agonist","levonorgestrel IUD","hormonal therapy","prehabilitation","minimally invasive surgery","robotic surgery","metabolic optimization","endometrial hyperplasia","weight loss intervention","endometrial cancer","endometrial carcinoma","early stage","obesity","cancer","real-world evidence","prospective","ClinicalTrial","wegovy","2026-06-06",{"date":135,"type":36},{"date":185,"type":22},"2027-01",{"date":187,"type":22},"2035-01",{"name":42,"class":43},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":215},"100430810","alnd-vs-art-in-positive-sentinel-node-after-neoadjuvant-therapy-in-breast-cancer-100430810","NCT04889924","ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer","Axillary Lymph Node Dissection Versus Axillary Radiotherapy in Breast Cancer Patients With Positive Sentinel Node After Neoadjuvant Therapy: A Multicenter Randomized Study","ADARNAT","Inclusion Criteria:\n\n* T1-T4 N0\u002F T0-T4 N1 at diagnosis and subsidiary of neoadjuvant treatment\n* Post-CT SLN with ≤2 macrometastasis\u002Fmicrometastasis or ITCs\n* Post-CT axillary response by ultrasound or MRI\n* Complete at least 70% of neoadjuvant chemotherapy and 6 months of endocrine treatment.\n\nExclusion Criteria:\n\n* cN2\n* ypN0\n* History of breast surgery for ipsilateral cancer in the last 10 years\n* History of other cancer in the last 5 years, except squamous carcinoma of the skin.",{"count":198,"type":22},820,[25],"In the case of primary surgery, in patients with sentinel node involvement, it has already been shown that omitting axillary lymph node dissection (ALND), often combining axillary radiotherapy (RT), does not worsen the prognosis and does significantly reduce the appearance of lymphedema. However, patients who have received neoadjuvant systemic treatment cannot benefit from this option, even though in the majority of those who have responded well to treatment, a residual disease in the armpit is low, but there are no studies yet published that supports the possibility of not performing lymphadenectomy.\n\nThe primary endpoint is to evaluate wether axillary radiotherapy (ART) presents a lower risk of lymphedema with respect to lymphadenectomy (ALND) in patients with breast cancer who, after neoadjuvant systemic treatment (NST), present the sentinel node affected. Likewise, we will evaluate recurrences and overall survival in both groups. Finally, we will analyze the quality of life of these patients.",[202,203,204,205,206],"Breast Cancer","Chemotherapy","Sentinel Lymph Node","Axillary Lymph Nodes Dissection","Radiotherapy Side Effect","2026-05-18",{"date":209,"type":36},"2026-05-19",{"date":211,"type":36},"2021-06-11",{"date":213,"type":22},"2028-12-31",{"name":42,"class":43},60,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":224,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":225,"targetDuration":227,"studyType":119,"phases":4,"briefSummary":228,"conditions":229,"keywords":233,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":79},"100635328","innate-immune-immunoparalysis-and-ventilator-associated-pneumonia-in-critically-ill-elderly-patients-100635328","NCT07551258","Innate Immune Immunoparalysis and Ventilator-Associated Pneumonia in Critically Ill Elderly Patients","Intensity and Duration of Innate Immune System Immunoparalysis in the Pathophysiology of Ventilator-Associated Pneumonia in Mechanically Ventilated Elderly Patients","IMP-VM","Inclusion Criteria:\n\n* ≥18 years\n* Mechanical ventilation expected \\>48h\n* Intubation between 24h pre- and 48h post- ICU admission\n* Informed consent\n\nExclusion Criteria:\n\n* Known severe immunosuppression, including primary immunodeficiency disorders, advanced HIV infection (AIDS), active hematological malignancy under treatment, recent chemotherapy or immunosuppressive therapy\n* High dose steroids at immunosuppressive doses\n* Active autoimmune disease\n* Pregnancy\n* End-of-life situation",true,{"count":226,"type":22},170,"90 Days","This prospective observational cohort study aims to evaluate the role of innate immune immunoparalysis in the development of ventilator-associated pneumonia (VAP) in critically ill mechanically ventilated patients. Immunoparalysis will be assessed through monocyte HLA-DR expression and ex vivo lipopolysaccharide (LPS)-stimulated TNF-α production.\n\nThe study will include three cohorts: elderly patients (≥65 years), younger adults (\\\u003C65 years), and healthy controls. The primary objective is to determine whether the presence, duration, intensity, and trend of immunoparalysis are associated with the incidence of VAP and other ICU-acquired infections. Secondary objectives include characterization of immunoparalysis dynamics, comparison of measurement methods, and evaluation of clinical outcomes.",[230,231,232],"Intubated ICU Patients","Ventilator Associated Pneumonia ( VAP)","Immunoparalysis",[234,235,236,237,238],"invasive mechanical ventilation","LPS stimulation","HLA-DR","innate immunity","ICU-acquired infections","2026-05-17",{"date":209,"type":36},{"date":242,"type":22},"2026-05-01",{"date":244,"type":22},"2028-07-31",{"name":42,"class":43},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":224,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":256,"conditions":257,"keywords":262,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":282,"leadSponsor":284,"locationsCount":285},"100633149","morphometric-study-of-the-female-pelvic-and-lower-abdominal-retroperitoneum-in-cadavers-100633149","NCT07522931","Morphometric Study of the Female Pelvic and Lower Abdominal Retroperitoneum in Cadavers","Systematic Anatomical Description of the Female Pelvic and Lower Abdominal Retroperitoneum: A Descriptive and Morphometric Cadaveric Study Oriented to Gynecologic Surgery","RETRO-PELVIS","Inclusion Criteria:\n\n* Female cadavers from an institutional body donation program\n* Age ≥ 18 years at time of death\n* Adequate preservation of pelvic and abdominal retroperitoneal structures\n* Anatomical integrity allowing identification of ureter, iliac vessels, hypogastric plexuses, aorta, and vena cava\n* Availability of both hemipelves for comparative analysis\n* Authorization for research use according to institutional body donation regulations\n\nExclusion Criteria:\n\n* Male cadavers\n* Prior major pelvic or abdominal surgery significantly altering retroperitoneal anatomy (e.g., hysterectomy, lymphadenectomy, vascular surgery)\n* History of pelvic or abdominal radiotherapy\n* Advanced pelvic or abdominal malignancy with retroperitoneal involvement\n* Severe trauma affecting pelvic or abdominal anatomy\n* Poor preservation or significant tissue degradation\n* Absence of one or both hemipelves\n* Advanced pregnancy at time of death",{"count":255,"type":22},20,"This study aims to provide a systematic anatomical and morphometric description of the female pelvic and lower abdominal retroperitoneum using cadaveric dissection, with direct application to gynecologic surgery.\n\nStandardized dissections will be performed in adult female cadavers obtained from a body donation program. Key anatomical structures, including the ureter, iliac vessels, aorta, inferior vena cava, hypogastric plexuses, and lymphatic territories, will be identified and measured. Spatial relationships, distances, and anatomical variations will be recorded using direct measurements and standardized photographic documentation.\n\nThe study will quantify anatomical variability and asymmetry between right and left hemipelves, focusing on ureteral, vascular, and neural structures. The results are expected to improve surgical planning, particularly in nerve-sparing techniques and pelvic and para-aortic lymphadenectomy, and to support the development of an applied anatomical atlas for educational and clinical use.",[258,259,260,261],"Pelvic Anatomy","Retroperitoneum","Cadaveric Study","Surgical Anatomy",[263,264,265,266,267,268,269,270,271,272,273,274,275,276,277],"Pelvic anatomy","retroperitoneum","female pelvis","Dissection","cadaver","cadaveric model","surgical anatomy","Gynecologic surgery","Morphometric analysis","Anatomical variability","Nerve-sparing surgery","Pelvic vessels","Ureter anatomy","Hypogastric plexus","Pelvic lymphatic anatomy","2026-04-14",{"date":280,"type":36},"2026-04-17",{"date":278,"type":36},{"date":283,"type":22},"2026-11-30",{"name":42,"class":43},2,{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":79},"100621253","comparison-of-transmesocolic-versus-retromesenteric-reconstruction-in-cephalic-duodenopancreatectomy-fast-trial-100621253","NCT07368218","Comparison of Transmesocolic Versus Retromesenteric Reconstruction in Cephalic Duodenopancreatectomy (FAST Trial)","Randomized Clinical Trial on Morbidity, Psychological Impact, and Changes in Biomarker Concentration During the Perioperative Period Comparing Transmesocolic Versus Retromesenteric Reconstruction in Cephalic Duodenopancreatectomy (FAST Trial)","FAST","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Candidates for cephalic duodenopancreatectomy due to pancreatic pathology\n* Ability to complete follow-up questionnaires\n\nExclusion Criteria:\n\n* Emergency surgery\n* Participation in another clinical trial\n* Pregnancy or lactation\n* Severe psychiatric disorder that prevents follow-up\n* Inability to understand the information and sign study consent",{"count":295,"type":22},124,[25],"Objective: To compare the incidence of delayed gastric emptying (ISGPS 2007 criteria) between patients undergoing retromesenteric versus transmesocolic reconstruction after pancreaticoduodenectomy. Secondary objectives include evaluating overall postoperative morbidity (Clavien-Dindo ≥ Grade I) at 90 days, postoperative pancreatic fistula according to ISGPF criteria, 30- and 90-day mortality, differences in operative time and blood loss, hospital stay duration, exploratory analysis of inflammatory biomarkers in serum and drainage fluid, psychological impact using SCL-90-R scale, and postoperative quality of life using EORTC QLQ-C30 scale.\n\nMethods: Randomized, controlled, single-center superiority clinical trial with 1:1 allocation. One hundred twenty-four patients candidates for duodenopancreatectomy due to pancreatic pathology will be randomized using balanced blocks to transmesocolic (control) or retromesenteric (study) reconstruction. Randomization will be revealed after completing the resection phase. Primary intention-to-treat analysis will estimate relative risk with 95% CI for dichotomous variables, Kaplan-Meier survival analysis with log-rank test, and linear mixed models for repeated measures in quality of life outcomes. Follow-up will be 90 days for the primary endpoint, extending to 12 months for secondary objectives.",[299],"Pancreatic Cancer",[301,302,303],"duodenopancreatectomy","Pancreatic cancer","Delayed Gastric emptying","2026-01-18",{"date":306,"type":36},"2026-01-26",{"date":308,"type":22},"2026-01-31",{"date":310,"type":22},"2028-06",{"name":42,"class":43},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":79},"100499394","impact-of-systematic-shaving-on-margins-100499394","NCT05782686","Impact of Systematic Shaving on Margins","Reduction of Affected Margins in Conservative Surgery for Breast Cancer: Impact of Systematic Shaving in the Operating Room","Inclusion Criteria:\n\n1. Breast-conserving surgery.\n2. Imaging diagnosis as the only breast tumor focus according to mammography, breast ultrasound and\u002For nuclear magnetic resonance;\n3. Pathological diagnosis of carcinoma in situ or infiltrating\n4. Oncoplastic without associated flaps;\n\nExclusion Criteria:\n\n1. Male patients;\n2. Patients with a history of ipsilateral breast cancer.\n3. Oncoplastic that includes flaps\n4. Multifocality or multicentricity;\n5. Pregnant or lactating patient;\n6. Stage IV patients;\n7. Patients eligible for mastectomy;",{"count":320,"type":22},234,[25],"The objective of this clinical trial is to demonstrate the reduction of positive margins in the definitive pathology of patients undergoing breast-conserving surgery with the systematic shaving technique compared to conventional surgery, and the reduction of second interventions for margin enlargement.",[324,202,325],"Margin, Tumor-Free","Surgery","2025-09-08",{"date":328,"type":36},"2025-09-15",{"date":330,"type":36},"2020-10-07",{"date":332,"type":22},"2026-10-16",{"name":42,"class":43},{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":341,"targetDuration":343,"studyType":119,"phases":4,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":285},"100497929","tad-after-chemotherapy-in-locally-advanced-breast-cancer-100497929","NCT05763641","TAD After Chemotherapy in Locally Advanced Breast Cancer","Target Axillary Dissection After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer","Inclusion Criteria:\n\n* Axillary lymph node metastasis proven by cytology\n* Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)\n* Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria\n* Neoadjuvant chemotherapy\n\nExclusion Criteria:\n\n* cN3 verified by imaging tests\n* N2 due to internal mammary involvement (N2b).\n* Tumors whose surrogate molecular subtype is luminal A.\n* Patients undergoing neoadjuvant endocrine therapy\n* Patients with local recurrences and metastatic tumors.",{"count":342,"type":22},162,"3 Years","This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and\u002For cT4).",[204,202,346],"Locally Advanced",{"date":348,"type":36},"2025-09-10",{"date":350,"type":36},"2021-02-01",{"date":352,"type":22},"2026-06-01",{"name":42,"class":43},{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":362,"targetDuration":364,"studyType":119,"phases":4,"briefSummary":365,"conditions":366,"keywords":370,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":382},"100449140","endoscopic-ultrasound-guided-gastroenterostomy-nationwide-prospective-registry-100449140","NCT05128604","Endoscopic Ultrasound-Guided Gastroenterostomy Nationwide: Prospective Registry.","Introduction Of Endoscopic Ultrasound-Guided Gastroenterostomy Based On A Learning Protocol And Prospective Registry.","GESICA","Inclusion Criteria:\n\n* Age 18 years or more\n* Gastric outlet obstruction (GOO) caused by passable \u002Funpassable stenosis in the antrum-duodenal region, to malignant or non-malignant conditions\n* Patient capable of understanding and signing informed consent form\n* Patient understanding the type of study and complying with the follow-up of complementary tests during the study's duration\n\nExclusion Criteria:\n\n* Massive ascites.\n* Complete stenosis\n* Failure to sign informed consent form\n* Patients with intellectual handicap who are unable to understand the nature and possible consequences of the study, unless there is a competent legal representative\n* Patients unable to adhere to subsequent follow-up requirements\n* Severe coagulation disorder: INR \\> 1.5 not correctible with administration of plasma and\u002For platelets \\\u003C 50,000\u002Fmm3",{"count":363,"type":22},50,"6 Months","This is project of help and support for the introduction of the GASTROENTEROANASTOMOSIS technique guided by ENDOSCOPIC -ULTRASOUND (EUS-GE) in centers in Catalonia, facilitating a teacher training.\n\nThe main objective is facilitate a safe introduction of the technique, limiting technical failures, and if necessary, support in rescue techniques.\n\nThe goal of this interventional study is to assess the impact of a teaching and on live-support model in the introduction of the gastroenteroanastomosis technique, evaluating its effects in safety and the learning curve.\n\nregarding the results in safety and learning curve of for the introduction \\[type of study: observational study or clinical trial\\] is to \\[learn about, test, compare etc.\\] in \\[describe participant population\u002Fhealth conditions\\]. The main question\\[s\\] it aims to answer are:\n\n* \\[question 1\\]\n* \\[question 2\\] Participants will \\[describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items\\]. If there is a comparison group: Researchers will compare \\[insert groups\\] to see if \\[insert effects\\].",[367,368,369],"Endoscopic Surgical Procedure","Safety","Training",[371,372,373],"endoscopic ultrasound","gastroenterostomy","lumen apposing stent","2025-07-25",{"date":376,"type":36},"2025-07-29",{"date":378,"type":36},"2022-05-23",{"date":380,"type":22},"2026-09-24",{"name":42,"class":43},6,{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":53,"minAge":390,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":394,"conditions":395,"keywords":398,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":409,"locationsCount":79},"100477013","sarcopenia-in-colorectal-cancer-patients-intervention-study-100477013","NCT05491434","Sarcopenia in Colorectal Cancer Patients, Intervention Study","Intervention, Non-randomized Controlled, Non-masked and Comparative Study of Presurgical Conditioning in Colorectal Cancer Patients Who Present With Sarcopenia","Inclusion Criteria:\n\n* Age ≥ 70 years old,\n* Colon adenocarcinoma without synchronous metàstasis,\n* No urgent surgery,\n* ECOG performance status ≤ 2,\n* no pregnancy or lactation,\n* signature of the informed consent,\n* ability to comply with the study indications.\n\nExclusion Criteria:\n\n* rectal càncer,\n* Concomitant neoplastic disease in the last 5 years\n* medical or mental condition of the patient that compromises the authorization of informed consent,\n* Concomitant uncontrolled or stable medical condition,\n* Clinically significant heart disease (congestive heart failure, symptomatic coronary disease)\n* Refusal to participate in the study.","70 Years",{"count":392,"type":22},370,[25],"The sarcopenia is a new concept for evaluating the functional status of patients, introduced during the last 20 years. This is defined as the relationship between the deterioration of muscle mass and the decrease in strength, the metabolic rate, the aerobic capacity and subsequently the evaluation of the functional status. The sarcopenia has been estimated to affect 5% to 13% of people aged between 60 and 70 years, increasing from 11% to 50% in those aged 80 years and older. In a study by Lieffers et al. of a total of 234 patients with colorectal cancer, with a mean age of 63 years according to the values observed by Prado et al., the prevalence of sarcopenia would be around 39%, being able to reach up to 60% in patients with chronic diseases.\n\nThe goal of this study is to compare the cumulative incidence of post-surgical complications due to infection at 30 days between the group of patients without sarcopenia and the group of patients with sarcopenia with an intervention based on a nutritional supplement + physical exercise.",[60,396,397],"Postoperative Complications","Infection;Post Surg Procedure",[60,399,400,401,402],"Colon cancer","Postoperative complications","Inmunologic status","L3 CT image","2025-05-15",{"date":405,"type":36},"2025-05-20",{"date":407,"type":36},"2020-12-01",{"date":308,"type":22},{"name":42,"class":43},{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":420,"briefSummary":421,"conditions":422,"keywords":425,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":429,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":382},"100418936","prophylactic-cholecystectomy-in-midgut-nets-patients-who-require-primary-tumor-surgery-100418936","NCT04735198","Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.","Effectiveness of Prophylactic Cholecystectomy in Patients With Midgut Neuroendocrine Tumor (Jejunum, Ileum or Proximal Colon) Who Require Primary Tumor Surgery. Randomized, Proof of Concept Clinical Trial.","TNE-IDC-COLE","Inclusion Criteria:\n\n* Patients must grant the informed consent written, signed and dated.\n* Male or female older than 18 years old.\n* Radiological or histological diagnose of midgut NET that can be treated with surgery.\n* In case of female with childbearing age (time between menarche and menopause), a pregnancy test with negative result.\n* Neuroendocrine tumors located in any of the aforementioned locations.\n* Presence or not of distant metastasis.\n* Presencié or not of gallstones.\n* Capacity of follow up.\n\nExclusion Criteria:\n\n* Neuroendocrine tumors which are not located in jejunum or ileum (bronchial, gastric, pancreatic, descending colon, sigma or rectum.).\n* Patients that have gone through a previous bowel resection.\n* Patients with previous cholecystectomy.\n* Pacients with biliary stone disease.\n* Patients who are candidate to liver resection or liver transplant.\n* Patients with a gallbladder polyp bigger than 6 mm.\n* Pacients with one gallbladder sessile polyp, presence of more than one polyp or patients older than 50 years old with a polyp.\n* Refusal to participate.\n* Patients with previous history of malignant neoplasms in the last 5 years, except skin basal cell carcinoma, \"in situ\" cervical carcinoma or in situ carcinoma found in a polyp removed with a colonoscopy.\n* Medical criteria that doesn't consider the patient a candidate to participate in the study.",{"count":419,"type":22},100,[25],"The investigators want to study the effectiveness of prophylactic cholecystectomy in patients with midgut neuroendocrine tumor (jejunum, ileum or proximal colon) who require primary tumor surgery. When patients are diagnosed and are tributary to surgical treatment, the tumor might compromise vascularization, and patients need an extensive bowel resection. The patients might also receive medical treatment with somatostatin analogs. The combination of extensive bowel resection and medical treatment might increase gallbladder stones, but patients might not develop biliary stone disease, as in the general population, where 20% of the population have gallbladder stones but only a 10 to 15 % of the population will develop symptoms.\n\nThe idea comes from the lack of literature about the incidence of biliary Stone disease in patients with midgut NET tumors.\n\nIt's a multicentric, open-label and randomized clinical trial to evaluate the incidence of biliary stone disease in patients with midgut NET who require primary tumor surgery combined or not to cholecystectomy.\n\nOur hypothesis suggests that patients with midgut neuroendocrine tumor who require primary tumor resection without the combination of prophylactic cholecystectomy do not have an increased incidence of biliary stone disease two years after the surgery, regardless of treatment with SSA.",[423,424],"Midgut Carcinoid Tumor","Biliary Stones",[426,427,428],"Neuroendocrine tumor","prophylactic cholecystectomy","Biliary stone disease",{"date":405,"type":36},{"date":431,"type":36},"2021-01-20",{"date":433,"type":22},"2026-02-28",{"name":42,"class":43},{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":79},"100581561","intravenous-lacosamide-for-the-treatment-of-acute-pain-in-trigeminal-neuralgia-100581561","NCT06851910","Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia","Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia: A Prospective Observational Study","All patients diagnosed with trigeminal neuralgia who present to the emergency department of Hospital de Bellvitge for an acute pain exacerbation and are prescribed intravenous lacosamide as symptomatic pain treatment, according to the treating physician's discretion, will be considered for inclusion.\n\nInclusion Criteria:\n\n* Diagnosis of classical or idiopathic trigeminal neuralgia according to the criteria of the International Classification of Headache Disorders (ICHD-3).\n* Age over 18 years.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Contraindication for treatment with lacosamide (previous hypersensitivity reaction, known atrioventricular block).\n* Mental or psychiatric illness that interferes with the ability to understand and sign the informed consent.\n* Language barrier.\n* Lack of cooperation.",{"count":255,"type":22},"This prospective observational study evaluates the effectiveness and safety of intravenous lacosamide as a rescue treatment for acute pain in patients presenting to the emergency department with trigeminal neuralgia",[445],"Trigeminal Neuralgia",[447,448,449,450],"trigeminal neuralgia","lacosamide","acute treatment","rescue treatment","2025-04-27",{"date":453,"type":36},"2025-04-29",{"date":455,"type":36},"2025-04-21",{"date":457,"type":22},"2027-05",{"name":42,"class":43},{"id":460,"slug":461,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":466,"targetDuration":468,"studyType":119,"phases":4,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":79},"100542191","icg-vs-blue-patent-for-tad-in-cn1-breast-carcinoma-after-neoadjuvant-chemotherapy-100542191","NCT06339658","ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy","ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* Breast cancer cN+ patients who undergo neadjuvant treatment.\n\nExclusion Criteria:\n\n* Patients in whom there is a contraindication for the use of ICG.\n* Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.",{"count":467,"type":22},43,"2 Years","To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.",[202,471],"Axillary Metastases","2025-04-17",{"date":474,"type":36},"2025-04-22",{"date":476,"type":36},"2021-01-01",{"date":478,"type":22},"2026-01-01",{"name":42,"class":43},{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":488,"targetDuration":490,"studyType":119,"phases":4,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":79},"100587708","oscillometry-in-the-copd-exacerbator-phenotype-with-triple-inhaled-therapy-study-100587708","NCT06931899","Oscillometry in the COPD Exacerbator Phenotype With Triple Inhaled Therapy Study","Usefulness of Oscillometry in Assessing the Effectiveness of Inhaled Corticosteroides in Patients With COPD Exacerbator Phenotype","OCTRIS","Inclusion Criteria:\n\n1. Age over 18 years.\n2. Diagnosis of COPD.\n3. Severe-moderate COPD measured by FEV1 and stable.\n4. Patient receiving dual bronchodilation therapy (LABA\u002FLAMA) for at least the last 4 months prior to study inclusion and meeting clinical criteria to begin triple inhaled therapy.\n5. COPD exacerbations (COPD exacerbations).\n6. Blood eosinophils \\>100 cells\u002FmL in prior laboratory tests.\n7. Patient agrees to participate in the study and signs the informed consent form.\n\nExclusion Criteria:\n\n1. COPD in the last 4 weeks, with use of antibiotics or systemic corticosteroids.\n2. Chronic lung disease other than COPD.\n3. Severe heart failure, with frequent decompensation (in cases of mild decompensation or onset without severe heart disease, do not include the patient within 3 months of decompensation).\n4. Active neoplastic processes.\n5. Severe renal failure.\n\n5\\. ALT greater than 2.5 times the upper limit of normal. 6. Poorly controlled insulin-dependent diabetes or involvement of 1 or more organs.\n\n7\\. Positive COVID-19 test (do not include until 3 months after diagnosis by ART or COVID-19 PCR).\n\n8\\. Previous treatment with ICS in the last 4 months.",{"count":489,"type":22},63,"12 Weeks","The objective of this observational study is to determine the effectiveness of inhaled corticosteroids in patients with chronic obstructive pulmonary disease (COPD) and frequent worsening of their respiratory symptoms by using a device called an oscillometer. This instrument is capable of measuring bronchial obstruction and air trapping in the lungs through vibrations during normal breathing. The main question it seeks to answer is:\n\nCould oscillometry be useful in assessing the effectiveness of inhaled corticosteroids in patients with COPD exacerbations, in terms of bronchial obstruction and air trapping in the lungs? Patients who choose to participate will undergo oscillometry testing and complete standard COPD questionnaires during three follow-up visits spread over three months.",[493],"COPD (Chronic Obstructive Pulmonary Disease)",[495,496,497],"Oscillometry","COPD","Inhaled corticosteroids","2025-04-09",{"date":472,"type":36},{"date":501,"type":22},"2025-04",{"date":503,"type":22},"2026-08",{"name":42,"class":43},{"id":506,"slug":507,"hasResults":11,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":224,"sex":53,"minAge":18,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":285},"100483345","usefulness-of-icg-angiography-guided-thyroidectomy-for-preserving-parathyroid-function-100483345","NCT05573828","Usefulness of ICG Angiography-Guided Thyroidectomy for Preserving Parathyroid Function","Usefulness of ICG Angiography-Guided Thyroidectomy for Preserving Parathyroid Function. GuiArte Multicentric Randomized Study.","GuiArte","Inclusion Criteria:\n\n* Patients ≥ 18 years of age with a surgical indication for total thyroidectomy with or without central cervical lymph node dissection due to thyroid pathology.\n* The patient or their guardian, where applicable, has the capacity to understand the study and agrees to participate in it, signing the corresponding informed consent document.\n\nExclusion Criteria:\n\n* Previous surgical intervention on the thyroid or parathyroid gland.\n* Associated hyperparathyroidism that requires associating a parathyroidectomy in the same surgical act.\n* Patients with contraindications for the administration of ICG.\n* Current drug use or alcohol abuse that could interfere with compliance with the study requirements.\n* Participation in any other drug trials in the month prior to randomization.","100 Years",{"count":515,"type":22},394,[25],"Transient and\u002For permanent hypoparathyroidism is the most frequent complication after total thyroidectomy. The identification of the parathyroid glands and a correct dissection during thyroidectomy have been postulated as key factors for their preservation and, consequently, to prevent hypoparathyroidism. The use of indocyanine green (ICG) fluorescence has reliably predicted parathyroid glands functionality in the immediate postoperative period. Recently, it is proposed that showing the vascular map of the parathyroid glands before performing the thyroidectomy by means of ICG angiography prevent the development of postoperative hypoparathyroidism.\n\nThe goal of this multicentric study is to demonstrate that the preservation of the function of parathyroid glands is greater with use of arteriography than without.\n\nPatients will be divided in two groups. In the study group, the vascular map with ICG of parathyroid glands will be showed before performing the lobectomy. Once the lobectomy is done, the function of the glands will be assessed. Whereas in the control group, arteriography with ICG will only be carried out in order to check their function at the end of the lobectomy.\n\nResearchers will compare the study group and the control group to see which one present the lowest taxes of postoperative hypoparathyroidism.",[519],"Iatrogenic Hypocalcemia",[521,522,523],"hypocalcemia","ICG angiography","Guided thyroidectomy","2025-03-18",{"date":526,"type":36},"2025-03-19",{"date":528,"type":36},"2022-10-11",{"date":530,"type":22},"2025-12-31",{"name":42,"class":43},{"id":533,"slug":534,"hasResults":11,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":23,"phases":541,"briefSummary":542,"conditions":543,"keywords":548,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":4},"100554436","eoss-attr-study-ehealth-based-operative-support-system-in-attr-cm-100554436","NCT06499064","EOSS-ATTR Study (eHealth Based Operative Support System in ATTR-CM)","Information and Communications Technology (ICT)-based Modeling of Transthyretin-associated Amyloidosis Cardiomyopathies (ATTR-CM) Care: EOSS-ATTR Study (eHealth Based Operative Support System in ATTR-CM)","eOSS-ATTR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* HF diagnosis according to European Society of Cardiology (ESC)\n* Patients with a HF decompensation in the last 12 months\n* Confirmed diagnosis of ATTR-CM (ATTRv or ATTRwt)\n* Written informed consent\n\nExclusion Criteria:\n\n* Age\\\u003C18 years old\n* Participation in another clinical trial\n* Moderate or severe cognitive impairment without a competent caregiver\n* Lack of social support\n* Institutionalized patients\n* Life expectancy less than 1 year (excluding HF)\n* Institutional-based or end-of-life care\n* Serious psychiatric illness\n* Planned cardiac surgery\n* Planned heart transplantation or left ventricular assist device (LVAD) implant\n* Patients in haemodialysis program\n* The patient is unable or unwilling to give the informed consent to participate\n* The patient is considered an unsuitable candidate for this study according to the decision of the local investigator\n* Unstable patients with signs of fluid overload or low cardiac output",{"count":363,"type":22},[25],"Unicenter, proof-of-concept, prospective, randomised, controlled, open-label and blinded end-point adjudication trial to assess the effect on patient-reported outcomes measures (PROMs), patient-reported experience measures (PREMs) and clinical events of a mHealth-based comprehensive management program for patients with chronic heart failure (HF) due to transthyretin-associated amyloidosis (ATTR)-cardiomyopathy (CM) by means of remote daily telemonitoring of signs and symptoms and remote structured follow-up using videoconference.",[544,545,546,547],"Heart Failure","Amyloid Cardiomyopathy","ATTR Amyloidosis Wild Type","ATTR Gene Mutation",[549],"eHealth; mHealth; telemonitoring; ATTR, heart failure","2024-10-21",{"date":552,"type":36},"2024-10-23",{"date":554,"type":22},"2024-12-01",{"date":556,"type":22},"2026-03-15",{"name":42,"class":43},{"id":559,"slug":560,"hasResults":11,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":566,"briefSummary":567,"conditions":568,"keywords":573,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":79},"100525019","impact-of-the-implementation-of-a-telemedicine-program-on-patients-diagnosed-with-asthma-100525019","NCT06116292","Impact of the Implementation of a Telemedicine Program on Patients Diagnosed with Asthma","Inclusion Criteria:\n\n* Age ≥18 years with a diagnosis of asthma based on GEMA 5.2 2022.\n* Patients seen in the pulmonology service of the center.\n* Patients who have not previously received asthma education.\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Patient who does not have a mobile device with Android or IOS system.\n* Lack of minimum technological knowledge for the use of the application (ESTOI).\n* People who are participating or have participated in a clinical trial in the last 6 months.\n* Patients diagnosed with other respiratory diseases except for obstructive sleep apnea (OSA), Asthma-COPD overlap syndrome (ACOS).\n* Patients with palliative or severe chronic illnesses that limit their life expectancy.",{"count":565,"type":22},108,[25],"Introduction: Asthma is one of the most common chronic respiratory diseases worldwide. Despite the extensive knowledge of the condition and available therapeutic options, severe asthmatic patients have poor disease control in 50% of cases.\n\nObjective: To assess the impact of implementing a mobile application (ESTOI) in patients diagnosed with asthma on disease control, treatment adherence, and perceived quality of life.\n\nMethodology: A 52-week randomized clinical trial involving asthma patients receiving care at a highly specialized hospital in Spain. A total of 108 patients will be included and divided into two groups. The intervention group will receive more comprehensive monitoring than usual, including access to the ESTOI application. The Asthma Control Test (ACT) questionnaire will be used as the primary assessment variable. Other variables to be studied include the Inhaler Adherence Test (TAI), the number of exacerbations, peak expiratory flow, exhaled nitric oxide examination, hospital anxiety and depression scale, asthma quality of life questionnaire, forced spirometry parameters (FVC, FEV1, and reversibility), and analytical parameters (eosinophilia and IgE).",[569,570,571,30,572],"Asthma","Telemedicine","Adherence, Treatment","Control",[569,570,574,575,571],"Asthma Control","Quality of Live","2024-10-20",{"date":578,"type":36},"2024-10-22",{"date":580,"type":36},"2024-01-01",{"date":582,"type":22},"2026-12-31",{"name":42,"class":43},{"id":585,"slug":586,"hasResults":11,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":591,"targetDuration":593,"studyType":119,"phases":4,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":605,"locationsCount":79},"100555184","combination-of-the-vaginal-laser-with-a-moisturizing-and-repairing-niosomal-gel-in-the-treatment-of-genitourinary-syndrome-in-oncology-patients-100555184","NCT06508788","Combination of the Vaginal Laser With a Moisturizing and Repairing Niosomal Gel in the Treatment of Genitourinary Syndrome in Oncology Patients","Combinación Del láser Vaginal Con un Gel Niosomal Hidratante y Reparador en el Tratamiento Del síndrome Genitourinario en Pacientes oncológicas","Inclusion Criteria:\n\n* Patients with an established SGM diagnosis.\n* Patients with a history of neoplasia in whom the use of estrogens as the first alternative for the treatment of GMS is not recommended.\n\nExclusion Criteria:\n\n* Patients with concomitant vulvovaginal pathology.\n* Patients with a diagnosis of pelvic organ prolapse grade II or greater.",{"count":592,"type":22},30,"1 Year","Vaginal laser together with the use of moisturizing and repairing gels could be an effective therapy for the treatment of genitourinary syndrome in women with a history of neoplasia in whom the use of estrogens is not recommended.\n\nThe purpose of this study is to evaluate the effectiveness of vaginal laser together with adjuvant treatment with a hydrating and repairing niosomal gel as a beneficial treatment in this group of patients.",[596],"Genitourinary Syndrome of Menopause",[596,598],"CO2 laser","2024-07-26",{"date":601,"type":36},"2024-07-29",{"date":603,"type":36},"2024-07-01",{"date":35,"type":22},{"name":42,"class":43},{"id":607,"slug":608,"hasResults":11,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":23,"phases":615,"briefSummary":616,"conditions":617,"keywords":620,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":79},"100544981","eus-guided-cds-vs-ercp-as-first-line-in-malignant-distal-obstruction-in-borderline-disease-carpediem-2-trial-100544981","NCT06375954","EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial)","Endoscopic Ultrasound-Guided Biliary Drainage With Lumen-Apposing Stent vs Classical ERCP for First-line Therapy of Malignant Distal Biliary Obstruction in Borderline Disease: An Open-label, Multicenter Randomized Trial (CARPEDIEM-2 Trial)","Inclusion Criteria:\n\n* Malignant distal biliary obstruction diagnosed in patient considered BORDERLINE with biliary drainage indication: i) impaired hepatic enzymes (including hyperbilirubinemia) x3 times upper the superior normal value. ii) Radiologic singns of extrahepatic bile duct obstruction with presence of retrograde dilatation, of at least 12-mm axial diameter.\n* Consensual malignancy by a bilio-pancreatic multidisciplinar committe (histological confirmation is not mandatory)\n* Patient capable of understanding and\u002For singning the informed consent.\n* Patient who understands the type of study and will comply with all follow-up tests throughout its duration\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Severe coagulation disorder: INR \\> 1.5 non correctable with plasma administration and\u002For platelet count \\\u003C 50.000\u002Fmm3.\n* Distal malignant biliary strictures in patients considered directly resectable, non-surgical, unresectable, or palliative\n* Benign or uncertain etiology of biliary strictures or strictures located proximally or in close proximity to the hilum.\n* Patients with prior biliary stents or other biliary drainages (e.g., PTCD).\n* Altered intestinal anatomy due to prior surgery that prevents or hinders papillary access (e.g., gastric bypass, Billroth II, duodenal switch, Roux-en-Y).\n* Stenosis in the antral or duodenal region that prevents access to the duodenum and reaching the papilla.\n* Situations that do not allow for upper gastrointestinal endoscopy (e.g., esophageal stricture).\n* Patients with functional diversity, who lack the capacity to understand the nature and potential consequences of the study, except when a legal representative is available.\n* Patients incapable of maintaining follow-up appointments (lack of adherence).\n* Lack of informed consent.",{"count":614,"type":22},96,[25],"The aim of this clinical trial is to evaluate temporal delay (days) between biliary drainage (EUS-CDS vs ERCP as first line therapy) and chemotherapy start in patients with borderline distal malignant biliary obstruction.",[618,299,619],"Malignant Biliary Obstruction","Biliary Tract Neoplasms",[621,622,623,624,625,626],"Choledochoduodenostomy","Therapeutic endoscopy","Biliary Drainage","Lumen apposing metal stent","ERCP","Biliopancreatic malignancy","2024-04-18",{"date":629,"type":36},"2024-04-19",{"date":631,"type":22},"2024-05-01",{"date":633,"type":22},"2027-05-01",{"name":42,"class":43},{"id":636,"slug":637,"hasResults":11,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":641,"eligibilityCriteria":642,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":643,"targetDuration":343,"studyType":119,"phases":4,"briefSummary":645,"conditions":646,"keywords":648,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":79},"100500915","evaluation-of-the-functional-status-of-jejunoplasty-and-coloplasty-and-its-impact-on-quality-of-life-cerec-100500915","NCT05802459","Evaluation of the Functional Status of Jejunoplasty and Coloplasty and Its Impact on Quality of Life (CEREC)","Prospective Evaluation of the Functional Status of Jejunoplasty and Coloplasty in Patients Undergoing Complex Esophageal Reconstruction and Its Impact on Quality of Life (CEREC)","CEREC","Inclusion Criteria:\n\n* Adult patients (≥ 18 years of age) and of both gender.\n* Candidates for complete esophageal reconstruction with cervical anastomosis, regardless of the etiology of the esophagectomy.\n* Decision to indicate a coloplasty (+\u002F- supercharged) or jejunoplasty (free, pedunculated +\u002F- supercharged) as surgical technique after evaluation by the UREC Committee.\n* Acceptance to participate in the study and comply with the program of procedures (schedule of visits).\n* Signing of the informed consent.\n\nExclusion Criteria:\n\n* Patients who withdraw their informed consent at any time during the course of the study.",{"count":644,"type":22},36,"The goal of this prospective population-based cohort study is to assess:\n\n* The evolution of the functional status of patients undergoing complex esophageal reconstruction\n* Its impact on quality of life, depending on the type of conduit performed.\n\nParticipants\n\n* Will be asked to complete different quality of life questionnaires during every follow-up visit\n* Will undergo additional tests to assess functionality",[30,647],"Dysphagia",[649,650,651,652,647],"Esophageal reconstruction","Quality of life","Coloplasty","Jejunoplasty","2023-03-27",{"date":655,"type":36},"2023-04-06",{"date":657,"type":36},"2022-12-15",{"date":659,"type":22},"2027-09",{"name":42,"class":43},{"id":662,"slug":663,"hasResults":11,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":667,"eligibilityCriteria":668,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":23,"phases":670,"briefSummary":671,"conditions":672,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":79},"100412563","robot-assisted-thoracic-approach-versus-open-transthoracic-esophagectomy--100412563","NCT04652180","Robot-assisted Thoracic Approach Versus Open Transthoracic Esophagectomy .","Clinical Trial Of Safety Of Robot-assisted Thoracic Approach Verus Open Transthoracic Esophagectomy in Esophageal Cancer.","CIR·ROB","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically proven adenocarcinoma, squamous cell carcinoma, undifferentiated carcinoma or carcinoma of the gastro-esophageal junction (GEJ) Siewert I or II.\n* Surgical resectable (T1-4a, N0-3, M0).\n* Childbearing potential women (period between menarche and menopause), pregnancy negative test is mandatory.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Stage IV or GEJ Siewert III esophageal cancer.\n* Contraindication of transthoracic esophagectomy in two fields.\n* Pre- or concomitant cancer or conditions which interferes with the study (e.g. prior thoracic surgery or trauma. Rationale: these patients may undergo open resection).",{"count":565,"type":22},[25],"This is a randomized controlled trial designed to compare robot-assisted thoracic approach with open transthoracic esophagectomy (Ivor Lewis technique) as a surgical treatment for resectable esophageal cancer.\n\nIf our hypothesis is proved correct, robot-assisted thoracic approach will result in a lower percentage of respiratory and overall postoperative complications, lower blood loss, shorter hospital stay, but with at least similar oncologic outcomes and better postoperative quality of life compared with the open transthoracic esophagectomy (current standard).",[673,674,396],"Esophageal Cancer","Esophageal Carcinoma","2023-02-28",{"date":677,"type":36},"2023-03-01",{"date":679,"type":36},"2020-11-06",{"date":681,"type":22},"2026-12-30",{"name":42,"class":43},""]